Triochem Products
Healthcare
512101 BSE
Price unavailable
No trades in 1Y
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures · EPS basis: Standalone · TTM
- ROCE
- −4.37%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹330.60
- Book Value
- ₹478.88
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- —
- ROE
- −34.60%
- Dividend Yield
- 0.00%
- EBITDA
- −₹50.00 L
- 52W High
- —
- 52W Low
- —
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.02 times its book value
Weaknesses
2- Company has low interest coverage ratio.
- Company has a low return on equity of -15.6% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 3 | 11 | 5 |
| Oscillators | Bearish | 3 | 5 | 1 |
| Moving Averages | Bullish | 0 | 6 | 4 |
Oscillators
Bearish
Bearish
3
Neutral
5
Bullish
1
Overall
Bullish
Bearish
3
Neutral
11
Bullish
5
Moving Averages
Bullish
Bearish
0
Neutral
6
Bullish
4
Key readings
- RSI (14)
- 96.01
- Bearish
- MACD (12,26,9)
- —
- Neutral
- SMA (50)
- —
- Neutral
- SMA (200)
- —
- Neutral
As of , the latest day with price data, so these readings are not current.
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Turned negative |
| 1Y | Negative, widened by ₹0.02 Cr |
| TTM | Zero base |
Net profit
| 10Y | +37.09% |
|---|---|
| 5Y | Turned to profit |
| 3Y | Turned to profit |
| 1Y | Turned to profit |
| TTM | Turned to profit |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Outflow widened by ₹1.84 Cr |
| 1Y | Turned negative |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | No sales |
|---|---|
| 5Y | No sales |
| 3Y | No sales |
| 1Y | No sales |
| TTM | No sales |
Revenue by year
| Mar 2017 | ₹18.06 Cr |
|---|---|
| Mar 2018 | ₹34.99 Cr |
| Mar 2019 | ₹12.35 Cr |
| Mar 2020 | ₹20.03 Cr |
| Mar 2021 | ₹13.94 Cr |
| Mar 2022 | ₹8.82 Cr |
| Mar 2023 | ₹0.00 Cr |
| Mar 2024 | ₹0.00 Cr |
| Mar 2025 | −₹0.01 Cr |
| Mar 2026 | −₹0.03 Cr |
Net profit by year
| Mar 2017 | ₹0.58 Cr |
|---|---|
| Mar 2018 | ₹2.56 Cr |
| Mar 2019 | ₹0.74 Cr |
| Mar 2020 | ₹3.40 Cr |
| Mar 2021 | −₹0.45 Cr |
| Mar 2022 | ₹1.32 Cr |
| Mar 2023 | −₹0.89 Cr |
| Mar 2024 | −₹1.01 Cr |
| Mar 2025 | −₹0.40 Cr |
| Mar 2026 | ₹7.97 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.26 | 0.29 | 0.24 | 0.33 | 0.31 | 0.3 | 0.59 | 0.33 | 0.36 | 0.43 | 0.38 | 0.22 | 0.05 |
| Operating Profit | −0.26 | −0.29 | −0.24 | −0.33 | −0.31 | −0.3 | −0.59 | −0.33 | −0.36 | −0.43 | −0.38 | −0.22 | −0.05 |
| Other Income | 0.14 | −1.11 | 0.04 | 0.8 | 0.23 | 0.27 | 0.46 | 0.32 | 0.22 | 0.3 | 0.22 | 11.29 | 0.17 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.08 | 0 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0 | 0 |
| PBT | −0.14 | −1.42 | −0.22 | 0.45 | −0.1 | −0.05 | −0.17 | −0.03 | −0.16 | −0.15 | −0.17 | 10.99 | 0.12 |
| Tax % | −21.43% | −27.46% | −4.55% | 28.89% | −20% | −20% | −147.06% | 1400% | −75% | 33.33% | −23.53% | 24.2% | 25% |
| Net Profit | −0.11 | −1.03 | −0.2 | 0.32 | −0.08 | −0.04 | 0.09 | −0.45 | −0.03 | −0.19 | −0.13 | 8.33 | 0.09 |
| EPS (₹) | −4.49 | −42.04 | −8.16 | 13.06 | −3.27 | −1.63 | 3.67 | −18.37 | −1.22 | −7.76 | −5.31 | 340 | 3.67 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.68 | 23.11 | 18.06 | 34.99 | 12.35 | 20.03 | 13.94 | 8.82 | 0 | 0 | −0.01 | −0.03 | 0 |
| Expenses | 29.44 | 22.11 | 17.07 | 31.18 | 10.71 | 15.48 | 14.3 | 7.47 | 1.33 | 1.05 | 1.21 | 1.34 | 1.08 |
| Operating Profit | 1.24 | 1 | 0.99 | 3.81 | 1.64 | 4.55 | −0.36 | 1.35 | −1.33 | −1.05 | −1.22 | −1.37 | −1.08 |
| OPM % | 4.04% | 4.33% | 5.48% | 10.89% | 13.28% | 22.72% | −2.58% | 15.31% | — | — | — | — | — |
| Other Income | 0.08 | −0.01 | 0.16 | 0.41 | 0.06 | 0.47 | 0.13 | 0.55 | 0.27 | −0.19 | 1.05 | 12.03 | 11.98 |
| Interest | 0.45 | 0.2 | 0.07 | 0.4 | 0.46 | 0.3 | 0.21 | 0.02 | 0 | 0 | 0 | 0.1 | 0.08 |
| Depreciation | 0.32 | 0.27 | 0.28 | 0.25 | 0.21 | 0.17 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.05 | 0.03 |
| PBT | 0.55 | 0.52 | 0.8 | 3.57 | 1.03 | 4.55 | −0.58 | 1.76 | −1.17 | −1.33 | −0.25 | 10.51 | 10.79 |
| Tax % | 23.64% | 32.69% | 28.75% | 28.57% | 29.13% | 25.27% | −24.14% | 25% | −24.79% | −24.06% | 60% | 24.17% | — |
| Net Profit | 0.42 | 0.34 | 0.58 | 2.56 | 0.74 | 3.4 | −0.45 | 1.32 | −0.89 | −1.01 | −0.4 | 7.97 | 8.1 |
| EPS (₹) | 17.14 | 13.88 | 23.67 | 104 | 30.2 | 139 | −18.37 | 53.88 | −36.33 | −41.22 | −16.33 | 325 | 331 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Reserves | 4.31 | 4.65 | 5.24 | 7.79 | 8.53 | 11.93 | 11.47 | 12.8 | 11.35 | 14.38 | 13.42 | 20.4 |
| Borrowings | 3.5 | 0 | 2.86 | 2.28 | 5.79 | 2.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.42 | 2.12 | 1.93 | 1.47 | 0.58 | 1.94 | 0.38 | 0.28 | 0.24 | 0.25 | 0.23 | 0.23 |
| Total Liabilities | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.1 | 13.33 | 11.84 | 14.88 | 13.9 | 20.88 |
| Fixed Assets | 1.72 | 1.85 | 1.64 | 1.42 | 1.22 | 1.06 | 0.94 | 0.87 | 0.77 | 0.68 | 0.6 | 0 |
| CWIP | 0.37 | 0.04 | 0 | 0 | 0 | 0.03 | 0.03 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.12 | 3.68 | 0 | 0 | 0 | 0 | 0 | 0 | 9.42 | 11.07 | 10.63 | 7.89 |
| Other Assets | 6.27 | 1.45 | 8.64 | 10.37 | 13.93 | 15.53 | 11.13 | 12.46 | 1.65 | 3.13 | 2.67 | 12.99 |
| Total Assets | 8.48 | 7.02 | 10.28 | 11.79 | 15.15 | 16.62 | 12.1 | 13.33 | 11.84 | 14.88 | 13.9 | 20.88 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 2.34 | 6.79 | −6.48 | 1.45 | −3.75 | 3.82 | 10.25 | 3.47 | −1.03 | −3.76 | 0.2 | −2.87 |
| Investing | −0.1 | −3.7 | 3.71 | −0.01 | 0.02 | −0.03 | 0 | 0.16 | −9.82 | 3.34 | 0.17 | 13.7 |
| Financing | −1.69 | −3.68 | 2.8 | −0.92 | 3.06 | −3.49 | −2.61 | −0.02 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0.56 | −0.59 | 0.03 | 0.52 | −0.67 | 0.3 | 7.64 | 3.61 | −10.85 | −0.42 | 0.37 | 10.82 |
| Free Cash Flow | 2.24 | 6.68 | −6.51 | 1.42 | −3.76 | 3.79 | 10.23 | 3.44 | −1.03 | −3.76 | 0.2 | 8.85 |
| CFO/EBITDA | 241 | 682 | −635 | 56 | −176 | 106 | −2,939 | 287 | 105 | 351 | −17 | 64 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2.02 | 0 | 49.52 | 0 | 98.42 | 226 | 36.4 | 0 | — | — | — | — |
| Inventory Days | 55.65 | 5.85 | 52.93 | 104 | 414 | 41.57 | 24.6 | 2.9 | — | — | — | — |
| Days Payable | 1.45 | 31.02 | 36.57 | 9.13 | 14.72 | 19.85 | 9.26 | 9.85 | — | — | — | — |
| Cash Conversion Cycle | 56.22 | −25.17 | 65.88 | 95.24 | 498 | 248 | 51.74 | −6.95 | — | — | — | — |
| Working Capital Days | 16.06 | −19.43 | 63.06 | 56.23 | 217 | 191 | 63.1 | 0.83 | — | — | — | — |
| ROCE % | 11.78% | 11.57% | 12.83% | 42.53% | 11.97% | 33.16% | −2.8% | 14.45% | −10.14% | −2.67% | −3.32% | −4.37% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Triochem Products insights
64 extracted metrics across FY10–FY27.
Documents
- General announcements 16 Oct 2026
Frequently Asked Questions about Triochem Products
What does Triochem Products Ltd do?
Triochem Products engaged primarily in the business of manufacturer and exporter of pharlnaceuticals products, Apls and chemicals.
Where is Triochem Products Ltd (TRIPR) listed?
Triochem Products Ltd trades under code 512101 on the BSE.
Which sector does Triochem Products Ltd belong to?
Triochem Products Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the Return on Equity (ROE) of Triochem Products Ltd?
Triochem Products Ltd reported a return on equity of -34.60%. Its debt-to-equity ratio is 0.00.
Company Information
Triochem Products engaged primarily in the business of manufacturer and exporter of pharlnaceuticals products, Apls and chemicals.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/512101.md for Triochem Products Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.